Renaissance Technologies LLC Sells 370,800 Shares of BioAtla, Inc. (NASDAQ:BCAB)

Renaissance Technologies LLC lowered its stake in shares of BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 37.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 625,500 shares of the company's stock after selling 370,800 shares during the quarter. Renaissance Technologies LLC owned about 1.30% of BioAtla worth $857,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in BCAB. Chase Investment Counsel Corp bought a new stake in shares of BioAtla in the first quarter valued at approximately $263,000. Dimensional Fund Advisors LP boosted its position in shares of BioAtla by 28.3% in the second quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company's stock valued at $458,000 after acquiring an additional 73,598 shares during the period. Perceptive Advisors LLC bought a new stake in shares of BioAtla in the fourth quarter valued at approximately $180,000. PVG Asset Management Corp bought a new stake in shares of BioAtla in the fourth quarter valued at approximately $161,000. Finally, Acadian Asset Management LLC boosted its position in shares of BioAtla by 57.6% in the first quarter. Acadian Asset Management LLC now owns 155,188 shares of the company's stock valued at $532,000 after acquiring an additional 56,748 shares during the period. Institutional investors own 77.23% of the company's stock.

Analyst Ratings Changes

Separately, JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of BioAtla in a research note on Monday, September 16th.

BioAtla Stock Down 4.7 %

BioAtla stock traded down $0.10 during mid-day trading on Tuesday, hitting $2.05. 1,169,359 shares of the company were exchanged, compared to its average volume of 833,991. BioAtla, Inc. has a 1-year low of $1.14 and a 1-year high of $4.02. The business has a fifty day moving average of $1.75 and a 200 day moving average of $2.06. The company has a market capitalization of $98.64 million, a PE ratio of -0.86 and a beta of 1.06.

BioAtla (NASDAQ:BCAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.01. During the same quarter in the prior year, the firm earned ($0.75) EPS. Research analysts expect that BioAtla, Inc. will post -1.52 earnings per share for the current year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.